spidiman

December 10th - 12th, 2012, Graz, Austria (Medical University of Graz)

Within the scope of the EU project "SPIDIMAN" a new glucose sensor technology is being developed which improves glucose measurement and allows a more exact insulin delivery which leads to a better blood glucose setting in patients with type 1 diabetes. Special target groups of the project are children and adolescents. JOANNEUM RESEARCH coordinates this four year project which comprises a consortium of nine multidisciplinary national and international partners.


The new glucose sensor technology is a so-called “single-port system” which allows glucose measurement and insulin delivery at the same site in the adipose tissue. Together with the insulin delivery needle special the optical glucose sensors are placed into the adipose tissue. The sensors are read-out by a miniaturized measuring device which is placed on the skin. Subsequently, glucose values are calculated.


Now, the new technology was tested in a first clinical study in humans. From a technical point of view, the tested single-port system is comparable with systems currently available on the market. In this first study important knowledge was obtained to further improve and advance the combination of glucose measurement and insulin delivery. This  single-port technology has a great potential to become the central element of an artificial pancreas system.

csm Spidiman mockup Generation 2 small 02 082a56412d

Rumpler, M., Mader, J.K., Fischer, J.P., Thar, R., Granger, J.M., Deliane, F., Klimant, I., Aberer, F., Sinner, F., Pieber, T.R., Hajnsek, M., 2016. First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus. URL: Biosens. Bioelectron. doi:10.1016/j.bios.2016.08.039

SPIDIMAN study in humans evaluates sensor performance

With the start of the clinical trial a major milestone within the SPIDIMAN project was achieved leading the project from the technical development phase to the clinical evaluation phase. With successfully completed biocompatibility tests, the clinical trial started end of July and is conducted at the Clinical Research Center of the Medical University of Graz. 12 type 1 diabetic patients volunteered to take part in the study. Each of them will wear two SPIDIMAN glucose readers to assess the sensor performance of the SPIDIMAN system. The 12h sensor tests are planned to start at 8 am in the morning and end at 8 pm in the evening, while glucose dynamics will be induced by high glycemic index breakfast and lunch followed by late and overdosed insulin boli. Reference blood glucose values were taken every 5 min throughout the study.

The statistical data analysis of this study is planned to be finished in October.

Proband

 

 

 

 

 

 

 

 

 

For further information about the ongoing SPIDIMAN progress, please feel free to contact us via This email address is being protected from spambots. You need JavaScript enabled to view it.

 

We are proud to inform you, that SPIDIMAN was awarded the "HTI: Human Technology Interface” price in the category “economic applications”. This price has been awarded by the state government of Styria in Graz on 29th of April, 2015.

Download press release

 Spidiman Preisverleihung

Landesrat Mag. Christopher Drexler, awardee DI Dr. Martin Hajnsek and Univ.-Prof. Dr. Wolfgang Pribyl (CEO JOANNEUM RESEARCH) at the awards ceremony © Werner Krug

Contact:
DI Dr. Martin Hajnsek
Tel.  +43 (0)316 876-4123
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.